Skip to main content
. 2024 May 3;144(2):156–170. doi: 10.1182/blood.2023021985

Figure 2.

Figure 2.

Kinase-inactivated CDK6 maintains HSPC potential upon long-term challenge. (A) Experimental workflow of repetitive in vivo pI:pC injections followed by an in vitro serial plating assay of Cdk6+/+, Cdk6–/–, and Cdk6KM/KM BM cells. (B) Flow cytometry analysis of L–K+CD86+ and HSC-MPP1 (from L–K+CD86+) cells upon serial pI:pC injection (n ≥ 3, mean ± SEM). (C) Cell cycle distribution of HSC/MPP1 cells upon serial pI:pC treatment (n=5, mean ± SEM). (D) Representative flow cytometry plots showing serially plated LSK cells upon repetitive pI:pC treatment. (E) Relative quantification of LSK cells during serial plating after repetitive in vivo pI:pC treatment (n = 3-6, mean ± SEM). SP, serial plating. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001.